Healthcare · Biotech & pharma
TME Pharma provides update on its activities
TME Pharma enters final evaluation phase with two potential partners for licensing lead asset NOX-A12 to support Phase 2 glioblastoma development
Aug 24 · 06:05GlobeNewswire
2,126 press releases in English indexed under biotech & pharma.
TME Pharma enters final evaluation phase with two potential partners for licensing lead asset NOX-A12 to support Phase 2 glioblastoma development
VILLEJUIF, France, August 24, 2026--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces the signing of a definitive share purchase agreement (the "SPA") and of the related contribution agreement (the "Contribution Agreement") for the acquisition of 100% of the share capital and voting rights of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"), bas
NEW YORK, Aug. 23, 2026 -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), today announced the enrollment of the first two patients in its PULSE-LHD clinical trial, conducted under a U.S. Food and Drug...
SEONGNAM, South Korea, Aug. 23, 2026 -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California. Lilly Gateway Labs is a...
SHANGHAI and HONG KONG, Aug. 23, 2026 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
New York, New York--(August 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
New York, New York--(August 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14,...
TAIPEI, Aug. 23, 2026 -- Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate...
SINGAPORE, August 23, 2026--Novotech, a leading global biotech full service CRO, has strengthened its established presence in Japan with the opening of a new office in Tokyo.
New class action for Regeneron (REGN) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/14/2026
New class action for Capricor (CAPR) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/28/2026
New York, New York--(August 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...